SHREE GANESH REMEDIES LIMITED Shree Ganesh Remedies Limited Share Price
Equities
SGRL6
INE414Y01015
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 618 INR | +0.46% |
|
-2.01% | -9.47% |
| 04-17 | Shree Ganesh Remedies Begins Trial Run of Plant in Gujarat, India | MT |
| 03-15 | Shree Ganesh Remedies Limited Announces Company Secretary and Compliance Officer Changes | CI |
| Sales 2022 | 713M 8.55M 682M | Sales 2023 | 902M 10.82M 863M | Capitalization | 3.1B 37.13M 2.96B |
|---|---|---|---|---|---|
| Net income 2022 | 134M 1.61M 128M | Net income 2023 | 170M 2.04M 163M | EV / Sales 2022 | 4.94 x |
| Net cash position 2022 | 38.83M 466K 37.17M | Net Debt 2023 | 224M 2.68M 214M | EV / Sales 2023 | 3.68 x |
| P/E ratio 2022 |
26.6
x | P/E ratio 2023 |
18
x | Employees | 110 |
| Yield 2022 |
0.17% | Yield 2023 |
0.2% | Free-Float | 20.2% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.46% | ||
| 1 week | -2.01% | ||
| Current month | -7.38% | ||
| 1 month | -8.48% | ||
| 3 months | -11.03% | ||
| 6 months | +28.47% | ||
| Current year | -9.47% |
1 week
603.00
660.00
1 month
581.00728.00
Current year
581.00736.00
1 year
282.20736.00
3 years
213.20736.00
5 years
42.96736.00
10 years
22.23736.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 26/04/95 | |
| Director of Finance/CFO | - | 17/01/21 | |
| Comptroller/Controller/Auditor | - | 18/07/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 26/04/95 | |
| Director/Board Member | 34 | 28/07/17 | |
| Director/Board Member | 33 | 10/10/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 618 | +0.46% | 1 756 |
| 30/04/24 | 615.2 | -0.86% | 2,929 |
| 29/04/24 | 620.6 | -1.59% | 5,111 |
| 26/04/24 | 630.6 | +0.91% | 3,249 |
| 25/04/24 | 625 | -0.77% | 3,269 |
Delayed Quote Bombay S.E., May 02, 2024 at 08:18 am
More quotes
Shree Ganesh Remedies Limited is an India-based company, which is engaged in the business of bulk drug intermediates. The Company is a supplier of pharmaceutical intermediates and specialty chemicals with chlorination, Grignard reaction, hydrogenation, and high-vacuum distillation. The Company's products include intermediates by active pharmaceutical ingredient (API), and fine and specialty chemicals. It offers services, including customized chemistry and manufacturing, assets and infrastructure and key technologies and expertise. It offers its solutions to the markets, such as life sciences: human health and veterinary, flavor and fragrance, polymer industries, electronics, and agro chemicals. The Company has a portfolio of approximately 39 drug intermediates, and 18 specialty chemical products. It also delivers a service of contract manufacturing for chemical reactions like amination, amidation, alkylation, bromination, catalytic hydrogenation and chlorination.
Calendar
28/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.47% | 94.7M | |
| +0.67% | 42.4B | |
| +45.83% | 40.04B | |
| -6.20% | 28.31B | |
| +6.55% | 24.94B | |
| -21.66% | 18.96B | |
| +29.96% | 12.3B | |
| -1.57% | 11.95B | |
| +16.03% | 11.32B | |
| -4.80% | 11.55B |
- Stock Market
- Equities
- SGRL6 Stock
